Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 10, 2025

Primary Completion Date

April 1, 2027

Study Completion Date

April 1, 2027

Conditions

Myelodysplastic SyndromesAcute Myeloid Leukemia

Interventions

DRUG

Tranexamic acid

Tranexamic acid 1000mg orally two or three times daily

DRUG

Placebo

Placebo orally two or three times daily

Trial Locations (1)

RECRUITING

CancerCare Manitoba, Winnipeg

All Listed Sponsors

lead

University of Manitoba

OTHER

NCT06599762 - Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter